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Abstract 
Interleukin-36 cytokines are predominantly expressed by epithelial cells. Significant 
upregulation of epidermal IL-36 is now a recognised characteristic of psoriatic skin 
inflammation.  IL-36 is known to induce inflammatory responses in dendritic cells, 
fibroblasts and epithelial cells. Although vascular alterations are a hallmark of psoriatic 
lesions and dermal endothelial cells are well known to play a critical role in skin 
inflammation, the effects of IL-36 on endothelial cells are unexplored. 
We here show that endothelial cells including dermal microvascular cells express a 
functionally active IL-36 receptor. Adhesion molecules VCAM-1 and ICAM-1 are 
upregulated by IL-36Ȗ stimulation and this is reversed by the presence of the endogenous IL-
36 receptor antagonist. IL-36Ȗ stimulated endothelial cells secrete the proinflammatory 
chemokines IL-8, CCL2 and CCL20.  Chemotaxis assays showed increased migration of T 
cells following IL-36Ȗ stimulation of endothelial cells.  These results suggest a role for IL-
36Ȗ in the dermal vascular compartment and it is likely to enhance psoriatic skin 
inflammation by activating endothelial cells and promoting leukocyte recruitment. 
 
Introduction 
Interleukin-36 (IL-36) cytokines are part of the wider IL-1 family and include IL-36Į, IL-
36ȕ, IL-36Ȗ and their inhibitor, the IL-36 receptor antagonist (IL-36Ra)(1).  IL-36 binds to 
the IL-36 receptor (IL-36R) and this is followed by recruitment of an accessory protein (IL-
RAcP), which is shared by other IL-1 members(2). Downstream intracellular signalling 
results in NF-țB and AP-1 activation and the expression of proinflammatory mediators in 
susceptible cells.  Whilst the receptor antagonist is able to bind to the receptor, it does not 
recruit the AcP receptor, so signaling does not occur and thus the Ra exerts antagonist 
effects(3, 4).  IL-36Ȗ is thought to be mainly produced by keratinocytes and other epithelial 
cells in response to stimuli such as fungi, inflammatory mediators such as TNF-Į and IL-1, 
bacteria, rhinovirus infection and smoke(5-9). IL-36 has stimulatory effects on a range of cell 
types including epithelial cells, fibroblasts and immune cells(6, 10-12).  IL-36 expressed by 
epithelial cells has been documented in several tissues including the lung; however, the 
majority of research has focused on the skin and specifically psoriasis(6). 
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Psoriasis is an immune mediated inflammatory disease affecting 2% of the world 
population(13).  Psoriasis pathology is associated with hyperkeratotic plaques and epidermal 
inflammatory cell infiltrates. This leads to visible raised erythematous scaly lesions. T cells 
and the adaptive immune system are key players in psoriasis. However, innate inflammatory 
mediators such as IL-1 family members, IL-23, IL-10 family members, CCL20, IL-8, TNF-Į 
and antimicrobial peptides are now well recognised for their role in both the initiation and 
maintenance of psoriatic inflammation(14, 15). 
IL-36Ȗ is highly up-regulated in psoriasis lesions on both the mRNA and protein level(16).  
Expression levels of IL-36Ȗ also correlate with levels of other cytokines such as IL-17, IL-23 
and TNFĮ in psoriasis lesions(5). Transgenic mice in which keratinocytes overexpress IL-36Į 
are susceptible to a psoriasis like inflammation following 12-O-Tetradecanoylphorbol-13-
acetate treatment(17). Using the same model, mice which were deficient in the IL-36Ra 
showed chronic skin abnormalities and enhanced plaque development. Mice deficient in the 
IL-36R were protected from plaque development(18). Also of note, generalized pustular 
psoriasis (GPP), a severe form of psoriasis, has been linked to loss-of-function mutations in 
the IL-36Ra  These mutations result in a less stable protein with resultant reduced control 
over IL-36 mediated responses(19). 
The pathophysiologic contribution of endothelial cells (ECs) in psoriatic inflammation is well 
recognised.  Psoriasis lesions show a developed vascular network, most notably in the 
papillary dermis.  Studies have confirmed these capillaries are wide, dilated, tortuous and 
leaky(20-22).  The combination of endothelial activation followed by angiogenesis leads to 
enhanced and sustained leukocyte recruitment/migration to the lesion and thus tissue 
inflammation(23, 24). Upregulation of adhesion molecules such as VCAM-1 (Vascular Cell 
Adhesion Molecule 1) and ICAM-1 (Intercellular Adhesion Molecule 1) has been detected, 
which increases adhesion of leukocytes and leads to extravasation(25). 
Several currently used medications for psoriasis may also work by affecting ECs along with 
immune cells. Methotrexate is thought to inhibit adhesion molecule expression(26). 
Moreover, Efalizumab, which was efficient for psoriasis treatment when available, works by 
blocking LFA-1(Lymphocyte function-associated antigen 1) on leukocytes so they are unable 
to bind to the adhesion molecule ICAM-1 on ECs(27). A number of proinflammatory 
cytokines upregulated in psoriatic lesions including TNF-Į and IL-17 are capable of 
activating ECs (23, 28). 
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The purpose of this study was to determine the effect of IL-36Ȗ on ECs.  
 
Methods 
Generation of IL-36 proteins 
As IL-36 and IL-36Ra both require N-terminal processing to become fully active(3), 
recombinant active forms of IL-36Ȗ (IL-36ȖS18) and IL-36Ra (IL-36 RaV2) were used 
throughout. Constructs of IL-36Ȗ S18 and IL-36 RaV2 containing N-terminal His-SUMO 
fusion partners were generated and expressed in BL21 (DE3) Codon + E. coli as described 
before(29).  Proteins were subsequently purified using Ni2+ -affinity and size exclusion 
chromatography. Once purified, the SUMO tag was removed using the Ulp1 protease, and the 
final active recombinant cytokines were purified by Ni2+ -affinity, ion exchange and size 
exclusion chromatography. 
 
Cell culture and stimulations 
Umbilical cords were supplied by Bradford Royal Infirmary under the approval and 
processing of Ethical Tissue Bradford.  HUVEC (Human Umbilical Vein Endothelial Cells) 
from 5 donors were isolated from umbilical cords in a previously described method(30). 
HDLEC (Human Dermal Lymphatic Endothelial Cells) from pooled donors were supplied 
from PromoCell (Heidelberg, Germany). Cells were incubated in an atmosphere of 95% 
humidity and 5% CO2 at 37°C.  All experiments were performed between the passages of 2-5 
for both cell types.  Endothelial cell media (PromoCell) was used containing 
penicillin/streptomycin (100U/100mg/ml) and fungizone (2.5 µg/ml) (both Life 
Technologies, Carlsbad, USA).  Cells were plated out on 6 well plates (Greiner Bio-One, 
Stonehouse, UK) pre coated with 10% v/v gelatine solution overnight.   Relevant cells were 
incubated with NF-țB inhibitor (IMD-0354) (Merck Millipore, Billerica,USA) 1µM for 1 
hour prior to stimulation.  The specificity of IMD-0354 at the doses used as previously been 
documented (31).  
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IL-36 Receptor confirmation by quantitative PCR (qPCR) 
Cells were washed with PBS and RNA was isolated using Quick-RNA MiniPrep (Zymo 
Research, Irvine, USA) according to the manufacturer's instructions. RNA was converted to 
cDNA using RevertAid first strand cDNA synthesis kit  (Thermo Scientific, Waltham, USA), 
according to the manufacturer's instructions. cDNA from previously isolated and cultured 
primary human primary keratinocytes and fibroblasts were used as positive controls(32). 
Quantitative PCR (q-PCR) was conducted using the CFX Connect™ Real-Time PCR 
Detection System. Reaction was performed using the QuantiFast SYBR Green PCR Kit 
(Qiagen). Primers for the IL-36R (IL1RL2) were purchased from Qiagen. Data was analysed 
using BIO-RAD CFX manager software version 3.0.  Results were normalised against the 
housekeeping gene U6snRNA.  The ratio between Ct value for the target gene and the Ct 
value for the housekeeping gene was then calculated. The average values for the different cell 
types were then expressed as a ratio of the keratinocyte value (1.00).  
 
IL-36 Receptor confirmation by Immunocytochemistry 
HUVEC and HDLEC were seeded onto gelatin coated coverslips overnight.  Cells were 
washed in TBS and fixed in 4% formaldehyde for 20 mins. Cells were then blocked for 1 
hour in 5% BSA in TBS.   Cells were incubated overnight with mouse anti-human CD31 
(1:1000) (Dako, Glostrup, Denmark) and rabbit anti-human IL-36R (1:500) (Novus 
Biologicals, Littleton, USA) or Rabbit IgG isotype control (1:500, Abcam, Cambridge, UK). 
Cells were washed with TBST and secondary donkey anti-rabbit Alexa 594 conjugated, and 
donkey anti-mouse Alexa 488 conjugated were added (both 1:1000, both Invitrogen, 
Carlsbad, USA). 
 
NF-țB and c-JUN analysis by Western Blot 
Cells were stimulated as before, for 1 hour. Cells were lysed with CelLytic M lysis buffer 
(Sigma-Aldrich), containing protease inhibitor cocktail (Roche Applied Bioscience, 
Rotkreuz, Switzerland) and phosphatase inhibitor (Thermo Scientific, Loughborough, UK).  
Protein concentration was determined by Bradford Assay and 20ug of total protein was 
separated on any kDa mini protean gel (Bio-Rad, Hemel Hempstead, UK).  Proteins were 
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blotted onto 0.2ௗȝm PVDF trans-blot pack (Bio-Rad).  Membranes were probed with either 
rabbit anti-human phospho-NF-țB (1:1000),rabbit anti-human Phospho-c-Jun (both Cell 
signalling Technology, Leiden, Netherlands),or mouse anti-human GAPDH (Santa Cruz 
Biotechnology, Dallas, USA), in Tris-buffered saline 0.1% Tween-20 (TBST) containing 5% 
BSA overnight at 4ௗ°C.  Mouse anti-rabbit or Donkey anti mouse, HRP-conjugated secondary 
antibodies were used at 1:5000 for 1 hour at room temperature.  
 
NF-țB and c-JUN activity by Immunocytochemistry 
Gelatin coated coverslips were placed into 6 well plates, and HUVEC cultured and stimulated 
as before.  Following 1 hour of treatment, cells were washed in TBS and fixed in 4% 
formaldehyde for 20 mins.  Cells were then blocked for 1 hour in 5% BSA in TBS.  Cells 
were then incubated overnight at 4ௗ°C with either rabbit anti-human phospho-NF-țB(1:1000) 
or rabbit anti-human phospho-c-JUN (1:1000) (both Cell signalling Technology, Leiden, 
Netherlands). Cells were washed with TBST and a secondary donkey anti-rabbit Alexa 594 
(1:1000) conjugated antibody was added.  Sheep anti-human Von Willebrand factor (FITC 
conjugated) (Abcam, Cambridge, UK) was used as a background stain.  
 
Chemokine analysis by ELISA 
Following stimulation, CCL2 and IL-8 concentrations were measured using ELISA kits from 
eBioscience (San Diego, USA). CCL20 was measured using R&D systems kit (Minneapolis, 
USA).  ELISAs were carried out according to the manufacturer’s protocols. Reproducibility 
of supernatants were confirmed by triplicate testing, with <10% error.  
 
Endothelial Cell adhesion molecule analysis by flow cytometry 
Following stimulation, cells were scraped in PBS. 1 x 105 cells per treatment were analysed. 
Cell surface Fc receptor block was performed with 5% BSA in PBS for 30 minutes, cells 
were then centrifuged and the supernatant discarded and the pellet resuspended in PBS. The 
following antibodies and relevant isotype controls (BioLegend, San Diego, USA) were then 
added, all at a 1 in 300 dilution: Alexa Fluor 488 anti-human CD54 (ICAM-1) and PE anti-
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human CD106 (VCAM-1).  After 1 hr incubation, cells were centrifuged, and pellets 
resuspended in PBS. Cells were then analysed by the Beckman Coulter CyAn™ ADP 
Analyser, using the Summit software version 4.1. 
 
Chemotaxis assay 
Chemotaxis plates (101-216, 8µm pore size) were purchased from Neuro Probe, USA.  30µl 
of supernatant was placed in the bottom chamber.  The porous insert was then placed on top.  
Blood was obtained from 7 healthy volunteers.  Mononuclear cells were isolated from blood 
by Lymphoprep density gradient centrifugation and resuspended in in RPMI containing 10% 
FCS. The suspension was then purified using a MACS magnetic separation column (Miltenyi 
Biotec) using microbeads for CD14 negative selection followed by CD4 positive selection.  T 
cell purity (<90%) was confirmed by FACS CD4/CD3 selection. Isolated T cells were 
resuspended in RPMI and 5 x 104  cells in 20 µl were added to the top chamber. Cells were 
incubated in an atmosphere of 95 % humidity and 5% CO2 at 37°C for 2 hours.  Following 
incubation, the suspension in the bottom chamber containing migrated cells was removed and 
placed in counting slides (BIO RAD, USA, 1450011).  The cell count was performed using 
the BIO RAD TC20 automated cell counter. The percentage of cells that had migrated was 
calculated for each treatment.  The percentage of cells that migrated for media only was set to 
0 and other treatment values were expressed as a migration index.  
 
Statistical analysis 
Statistical significance was calculated using a one-way ANOVA with a Bonferroni's multiple 
comparisons test, unless stated.  Analysis was performed using GraphPad Prism software 
(GraphPad Software Inc, La Jolla, CA, USA).  Error bars represent the standard error of the 
mean (SEM). *: p<0.05 from indicated controls.  
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Results 
The IL-36R is present on endothelial cells 
Whilst no stimulatory effects of IL-36 on ECs have previously been documented, expression 
of the IL-36 receptor (IL-36R) first needed to be confirmed.  For analysis of receptor 
expression, two different EC types were used, HUVEC (Human Umbilical Vein Endothelial 
Cells) and HDLEC (Human Dermal Lymphatic Endothelial Cells).  A range of cell types are 
known to express the IL-36R including fibroblasts and keratinocytes.  Keratinocytes are 
known to highly express the receptor when compared to other cell types and human T cells 
show no expression(10).  qPCR analysis confirmed expression of the IL-36R by both 
HUVEC and HDLEC (Figure 1A).   ICC expression confirmed the expression at protein level 
on both HUVEC and HDLEC (Figure 1B). 
 
IL-36 Ȗ activates NF-țB and c-JUN 
IL-36Ȗ stimulation resulted in increased NF-țB and c-JUN activation (Figure 2).  
Concentrations of 10 and 50ng/ml of IL-36Ȗ resulted in increased detection of the 
phosphorylated active versions of NF-țB and c-JUN (AP-1) in the nucleus of HUVEC and 
also in whole protein lysate.  The activation of both NF-țB and c-JUN was reduced by the 
addition of the RA.  NF-țB inhibitor only partially inhibited IL-8 secretion suggesting AP-1 
may also play a role (Figure 4A).  
 
Adhesion molecules ICAM-1 and VCAM-1 are upregulated following IL-36Ȗ 
stimulation 
Proinflammatory cytokines are known to upregulate adhesion molecules on ECs thereby 
facilitating leukocyte recruitment.  With regard to IL-36Ȗ FACS analysis confirmed both 
ICAM-1 and VCAM-1 were upregulated after stimulating ECs with IL-36Ȗ for 48 hr (Figure 
3).  HUVEC and HDLEC both showed adhesion molecule upregulation in a dose dependent 
manner.   Stimulation with 10 ng/ml showed minimal upregulation but 50 ng/ml of IL-36Ȗ 
resulted in a significant upregulation of surface expression of both ICAM-1 and VCAM-1. 
Median fluorescence intensity (MFI) of independent experiments was determined. Statistical 
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analysis performed showed the MFI for untreated controls was statistically significant when 
compared to IL-36 50 ng/ml MFI, for both cell types and adhesion molecules.  
 
Endothelial cells secrete chemokines following IL-36 stimulation 
To assess the functional significance of IL-36R receptor expression on ECs, chemokines 
known to be secreted by ECs that are of relevance for psoriatic inflammation were measured.  
Following 48 hr IL-36Ȗ stimulation, ECs supernatants were analysed for chemokines by 
ELISA. ECs secreted IL-8, CCL2 (MCP-1) and CCL20 in a dose dependent manner (Figure 4 
A-C).    ECs are known to react very sensitively to endotoxin contamination and for this 
reason the IL-36 preparation was boiled prior to stimulation to confirm no contamination was 
present.  Boiled controls subsequently produced similar secretion levels to untreated cells 
thus excluding endotoxin contamination in the recombinant protein.  Both 10 and 50 ng/ml of 
IL-36Ȗ resulted in significant chemokine production when compared to untreated control.   In 
the presence of the IL-36Ra secretion levels were reduced in a dose dependent manner and  
concentrations of 10, 50 and 100 ng/ml of the Ra all lowered secretions in comparison to IL-
36Ȗ stimulation alone. The effect of IL-36Ra also confirms the presence of the IL-36R on 
both EC types. 
 
Supernatant from IL-36Ȗ stimulated ECs is a chemoattractant for T cells 
Having observed chemokine secretion by ECs following IL-36Ȗ stimulation, the chemotactic 
potency of the endothelial cell conditioned media was assessed.  CCL20, which we found to 
be secreted by ECs following IL-36Ȗ stimulation is known to be a chemoattractant for 
lymphocytes and has a documented role in psoriasis(33).  Untreated cell supernatant, media 
alone and IL-36Ȗ + media were used as negative controls and rhCCL20 as a positive control.  
Supernatant from IL-36Ȗ stimulated ECs proved to be a chemoattractant for T cells when 
compared to negative controls (Figure 4D). A dose dependency for the IL-36Ȗ effect on 
endothelial cells’ capacity to increase T cell migration was seen.    Chemotaxis assays could 
confirm that IL-36Ra at 100 ng/ml was sufficient to inhibit the stimulatory effects of IL-36Ȗ 
10 ng/ml. When stimulating with the Ra at 100 ng/ml, the migration of T cells was reduced 
and comparable to untreated supernatant.  This suggests IL-36Ȗ induced chemokine secretion 
was indeed responsible for T cell migration.  
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Discussion 
Psoriasis is a common chronic inflammatory skin disorder affecting around 2% of the 
population.  The IL-1 family member, IL-36 has been linked to psoriasis pathogenesis and 
disease severity. In psoriasis and other inflammatory diseases, ECs are activated by 
proinflammatory cytokines, resulting in enhanced leukocyte recruitment.  However, so far the 
effect of IL-36 on ECs has been unexplored.  
Here, we describe that the IL-36 receptor is expressed by both HUVEC and HDLEC.  We 
assessed the functional activity of the receptor by assessing the biologic response of ECs to 
IL-36Ȗ stimulation, including adhesion molecule upregulation and chemokine production.  
Both adhesion molecules ICAM-1 and VCAM-1 were upregulated following IL-36Ȗ 
stimulation.  Adhesion molecules are involved in leukocyte extravasation, which allows the 
movement of leukocytes to the site of inflammatory responses. Selectins are responsible for 
the rolling and capture of leukocytes whereas ICAM-1 and VCAM-1 are involved in the 
adhesion and transmigration.  The integrins expressed on leukocytes, LFA-1 and VLA-4 
(Very Late Antigen-4) bind to ICAM-1 and VCAM-1 respectively(34). In the context of 
psoriasis pathogenesis, both these adhesion molecules are required for T cell adhesion and 
migration into the skin(17, 35). 
IL-36 stimulation and subsequent chemokine secretion has been shown to be dependent on 
the  activation of transcription factors AP-1 and NF-țB (36). We report activation of both 
these transcription factors in ECs (Figure 2). ECs responded with chemokine production to 
IL-36Ȗ stimulation.  CCL2 (MCP-1) has a documented importance in psoriasis and other 
inflammatory diseases by recruiting monocytes(37).  IL-8, which promotes neutrophil 
recruitment, EC survival and angiogenesis, was also secreted following IL-36Ȗ 
stimulation(38).  The importance of angiogenesis in psoriasis is well recognised(39), and 
local EC secretion of IL-8 induced by IL-36Ȗ could be a contributing factor. CCL20 was 
secreted, which binds to CCR6, which is highly expressed on IL-17 and IL-22 producing 
lymphocytes and the majority of T cells that infiltrate the skin in psoriasis are CCR6 
positive(33).  Chemotaxis assays confirmed increased T cell migration following IL-36Ȗ EC 
stimulation, which could be due to CCL20 secretion. Although keratinocytes are a main 
source of CCL20 (33, 40), our findings indicate that ECs can contribute to the cutaneous 
CCL20 as well as CCL2 production.  For all chemokines analysed, the IL-36Ra was able to 
dampen the effect in a dose dependent manner.  This finding was also mirrored in the 
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chemotaxis assay where T cell migration was reduced when cells had been co-stimulated 
with the Ra.   
It is hypothesized environmental triggers can cause keratinocytes to secrete IL-36Ȗ 
independently of proinflammatory cytokines such as TNFĮ(17, 35).  It is thus possible that 
IL-36Ȗ could be important in the initiation of EC activation. 
Our here presented findings could also have implications for other diseases.  Lung bronchial 
epithelial cells secrete IL-36Ȗ in response to cytokines such as TNFĮ(6). Cigarette smoke, the 
causative agent of Chronic Obstructive Pulmonary Disease (COPD) is also known to cause 
IL-36Ȗ secretion in bronchial epithelial cells(7). However, the exact role of IL-36 in 
respiratory disease is still unknown.  IL-36Į has been shown to be expressed in the synovium 
of both psoriatic and rheumatoid arthritis patients (41), while both Į and y have been 
implicated in Crohn's disease in mouse models (42).  In COPD, Crohn’s disease and 
rheumatoid arthritis, like many chronic inflammatory diseases, angiogenesis and EC 
activation occurs(43-45). Therefore IL-36 may also have a role in EC activation and 
leukocyte recruitment in these diseases.  Murine models of liver damage/liver inflammation 
have also identified enhanced expression of IL-36Ȗ, and elevated CCL20 levels(46). EC 
induced secretion of CCL20 by IL-36Ȗ could be one of the potential sources of this.  
IL-36Ȗ serum levels are enhanced in psoriasis patients(16). In recent years psoriasis has been 
suggested as an independent risk factor for atherosclerosis(47, 48).  In atherosclerosis, 
endothelium activation and initial inflammatory signalling represent an important stage of 
disease development(49). Increased serum levels of IL-36Ȗ and therefore possible increased 
endothelium activation of the arteries could accelerate atherosclerosis disease progression.  
Of note, generalised pustular psoriasis (GPP) can be associated with loss of function 
mutations in IL-36Ra  and results in reduced control over IL-36.  However the risk factor of 
GGP on cardiovascular disease is largely unexplored.   
In summary, our results suggest that IL-36Ȗ has a role in activating the endothelium further 
enhancing lymphocyte recruitment and thus enhancing psoriatic inflammation.  These 
findings add to the growing importance of IL-36Ȗ in both psoriasis initiation and 
maintenance.  Further studies will help decipher the significance of IL-36Ȗ and its 
interactions with other EC stimulating mediators such as TNF-Į and IL-17 in human psoriatic 
tissue. 
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Figure 1. Expression of the IL36R on human endothelial cells. A)qPCR was performed 
and relative mRNA expression determined.  Keratinocyte expression was set to 1.00 and 
HUVEC, HDLEC and fibroblast expression of the receptor was quantified relative to 
keratinocyte expression. Samples: HUVEC n = 5, HDLEC n=3 (pooled donors) 3 biological 
replicates,  keratinocytes, fibroblasts n=2.  Standard error of mean depicted on graph.  B) ICC 
confirmation of receptor on HUVEC and HDLEC. Magnification x 40. 
 
Figure 2. IL-36Ȗ induces NF-țB and c-JUN in HUVEC.  Western blot (A) and ICC 
analysis (B) of  pNF-țB-p65 and pc-JUN. Phosphospecific antibodies detect active form or 
NF-țB or c-JUN in the nucleus of HUVEC. Increased detection of active form of both 
detected in whole cell lysate via western blot.  Magnification x 40. 
Figure 3. Endothelial cell adhesion molecule upregulation following IL-36Ȗ stimulation. 
Following 48 hr stimulation with IL-36Ȗ, ECs (HUVEC and HDLEC) were stained with 
labelled antibodies specific for ICAM-1 or VCAM-1 and analysed by flow cytometry for 
surface expression.  Relevant isotype controls were used as negative control. Fluorescence 
beyond the “isotype” line in the depicted histograms thus represents specific binding of 
antibody demonstrating detectable expression. A representative experiment is shown (sample 
sizes: HUVEC n=3, HDLEC n=3).    
Figure 4. ECs secrete chemokines which are a chemoattractant for T cells. Following 
48hr stimulation, the cell supernatant was tested for CCL20, CCL2 and IL-8 by ELISA (A-
C). Sample sizes: HUVEC n=5, HDLEC n=3 (3 biological replicates of pooled donors). The 
supernatant from treated and untreated ECs was removed and tested for its chemoattractant 
ability using a chemotaxis assay. The supernatant was placed in the bottom chamber and T 
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cells above. The number of migrated cells in the bottom chamber was then measured. Sample 
size: n=7. Standard error of mean depicted.   ANOVA *: p<0.05 from relevant controls.  
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